Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 20;18(11):2471.
doi: 10.3390/ijms18112471.

Advanced Glycation End Products in the Pathogenesis of Psoriasis

Affiliations
Review

Advanced Glycation End Products in the Pathogenesis of Psoriasis

Anastasia Papagrigoraki et al. Int J Mol Sci. .

Abstract

Advanced glycation end products (AGEs) are extremely oxidant and biologically reactive compounds, which form through oxidation of sugars, lipids and amino acids to create aldehydes that bind covalently to proteins. AGEs formation and accumulation in human tissues is a physiological process during ageing but it is enhanced in case of persistent hyperglycemia, hyperlipidemia and oxidative or carbonyl stress, which are common in patients with moderate to severe psoriasis. Exogenous AGEs may derive from foods, UV irradiation and cigarette smoking. AGEs elicit biological functions by activating membrane receptors expressed on epithelial and inflammatory cell surface. AGEs amplify inflammatory response by favoring the release of cytokines and chemokines, the production of reactive oxygen species and the activation of metalloproteases. AGEs levels are increased in the skin and blood of patients with severe psoriasis independently of associated metabolic disorders. Intensified glycation of proteins in psoriasis skin might have a role in fueling cutaneous inflammation. In addition, AGEs released from psoriatic skin may increase metabolic and cardiovascular risk in patients with severe disease.

Keywords: advanced glycation end products; inflammation; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Metabolic pathways leading to the advanced glycation end products (AGEs) production.

Similar articles

Cited by

References

    1. Papagrigoraki A., Del Giglio M., Cosma C., Maurelli M., Girolomoni G., Lapolla A. Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis. Acta Derm. Venereol. 2017;97:782–787. doi: 10.2340/00015555-2661. - DOI - PubMed
    1. Monnier V.M., Cerami A. Nonenzymatic browning in vivo-possible process for aging of long-lived proteins. Science. 1981;211:491–493. doi: 10.1126/science.6779377. - DOI - PubMed
    1. Da Moura Semedo C., Webb M., Waller H., Khunti K., Davies M. Skin autofluorescence, a non-invasive marker of advanced glycation end products: Clinical relevance and limitations. Postgrad. Med. J. 2017;93:289–294. doi: 10.1136/postgradmedj-2016-134579. - DOI - PubMed
    1. Damasiewicz-Bodzek A., Wielkoszyński T. Advanced protein glycation in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2012;26:172–179. doi: 10.1111/j.1468-3083.2011.04024.x. - DOI - PubMed
    1. Singh R., Barden A., Mori T., Beilin L. Advanced glycation endproducts: A review. Diabetologia. 2001;44:129–146. doi: 10.1007/s001250051591. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources